New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections

被引:36
作者
Harder, TC
Hufnagel, M
Zahn, K
Beutel, K
Schmitt, HJ
Ullmann, U
Rautenberg, P
机构
[1] Food & Vet Diagnost Lab, D-24537 Neumunster, Germany
[2] Univ Kiel, Childrens Hosp, Kiel, Germany
关键词
D O I
10.1128/JCM.39.12.4413-4419.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Detection of parvovirus B19 DNA offers diagnostic advantages over serology, particularly in persistent infections of immunocompromised patients. A rapid, novel method of B19 DNA detection and quantification is introduced. This method, a quantitative PCR assay, is based on real-time glass capillary thermocycling (LightCycler [LC]) and fluorescence resonance energy transfer (FRET). The PCR assay allowed quantification over a dynamic range of over 7 logs and could quantify as little as 250 B19 genome equivalents (geq) per ml as calculated for plasmid DNA (i.e., theoretically greater than or equal to5 geq per assay). Interrater agreement analysis demonstrated equivalence of LC-FRFT PCR and conventional nested PCR in the diagnosis of an active B19 infection (kappa coefficient = 0.83). The benefit of the new method was demonstrated in an immunocompromised child with a relapsing infection, who required an attenuation of the immunosuppressive therapy in addition to repeated doses of immunoglobulin to eliminate the virus.
引用
收藏
页码:4413 / 4419
页数:7
相关论文
共 57 条
  • [1] A quantitative, internally controlled real-time PCR Assay for the detection of parvovirus B19 DNA
    Aberham, C
    Pendl, C
    Gross, P
    Zerlauth, G
    Gessner, P
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2001, 92 (02) : 183 - 191
  • [2] Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection
    Abkowitz, JL
    Brown, KE
    Wood, RW
    Kovach, NL
    Green, SW
    Young, NS
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (01) : 269 - 273
  • [3] GENERATION OF NEUTRALIZING ANTI-B19 PARVOVIRUS HUMAN MONOCLONAL-ANTIBODIES FROM PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    ARAKELOV, S
    GORNY, MK
    WILLIAMS, C
    RIGGIN, CH
    BRADY, F
    COLLETT, MS
    ZOLLAPAZNER, S
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (03) : 580 - 585
  • [4] Large-scale screening for human parvovirus B19 DNA by PCR: Application to the quality control of plasma for fractionation
    Aubin, JT
    Defer, C
    Vidaud, M
    Montreuil, MM
    Flan, B
    [J]. VOX SANGUINIS, 2000, 78 (01) : 7 - 12
  • [5] Broliden K, 1998, MED PEDIATR ONCOL, V31, P66
  • [6] Brown KE, 1997, ANNU REV MED, V48, P59
  • [7] Haematological consequences of parvovirus B19 infection
    Brown, KE
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2000, 13 (02) : 245 - 259
  • [8] BROWN KE, 1993, SCIENCE, V262, P115
  • [9] CARROLL J, 1993, PLOUGHSHARES, V19, P221
  • [10] Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual
    Cassinotti, P
    Siegl, G
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (11) : 886 - 887